Filing Flows › Volitionrx (VNRX) › R&D spending
Volitionrx (VNRX) R&D spending by quarter
Volitionrx's R&D spending was $1.8M in Q2 2026 (second quarter 2026), -37% from Q1 2026. Over the last 7 quarters it ranged from $1.8M (Q2 2026) to $2.9M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $1.8M | -37% | -34% |
| Q1 2026 | $2.9M | +16% | +9% |
| Q4 2025 | $2.5M | +8% | -5% |
| Q3 2025 | $2.3M | -16% | — |
| Q2 2025 | $2.7M | +4% | — |
| Q1 2025 | $2.6M | +0.8% | — |
| Q4 2024 | $2.6M | — | — |
Q2 2026 at a glance
Volitionrx, Q2 2026: revenue $399K (-2% year over year), net loss $7.3M, operating cash flow −$5.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Volitionrx's R&D spending?
Volitionrx's R&D spending was $1.8M in Q2 2026 (second quarter 2026), -37% from Q1 2026.
How has Volitionrx's R&D spending changed?
Over the last 7 quarters it ranged from $1.8M (Q2 2026) to $2.9M (Q1 2026).